Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Genzyme 1Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Genzyme 1Q11

Personalized Genetic Health business grew 11% to $436.9 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 1Q11

1Q Revenues: $1.0 billion (+7%)

Comments: Personalized Genetic Health business grew 11% to $436.9 million. Myozyme / Lumizyme sales grew 47% in the quarter to $126.8 million. Cerezyme sales were $183.8 million (+3%). Sales of Fabrazyme were down 23% to $40.9 million, reflecting supply constraints. The company’s Hematology and Oncology business grew 7% to $166.5 million, driven by U.S. growth of Clolar, continued market penetration of Mozobil, and growth of Thymoglobulin. Sales of Renvela and Renagel grew 14% to $187.4 million. Sales of Thyrogen were down due to supply shortages caused by manufacturing constraints. Genzyme was acquired by Sanofi-Aventis on April 8, 2011.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters